MedPath

Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases

Recruiting
Conditions
Rare Diseases
Genetic Predisposition
Registration Number
NCT03491280
Lead Sponsor
University Hospital Tuebingen
Brief Summary

The DiRiP study will enroll patients (n = 3500) with unclear rare diseases and suspected genetic reasons. In group 1 (n = 500) subjects are clinically characterized in the context of outpatient/ inpatient standard care at the UKT or cooperating location, NGS analyzes and other omics analyzes (transcriptomics, proteomics, metabolomics), functional cell biology studies will be performed. In group 2 diagnostics is already performed.

The DiRiP-study fully integrates with the newly formed European Reference Networks (ERNs) for rare diseases, and in particular the ERN-RND, -EURO-NMD, -ITHACA, and -GENTURIS.

Detailed Description

In the DiRiP-RD study (monocentric, prospective, open-label diagnostic study), patients with genetically unexplained diseases will be analyzed or re-analyzed from existing datasets for further omics analysis. These are evaluated with regard to the following questions:

Primary:

* Verification of the genetic causes of unclear genetic diseases

Secondary:

* Improve number of diagnoses of unclear syndromes

* Further characterization of the identified gene defects

* Number of patients receiving appropriate therapy after successful diagnosis. In addition, patient phenotype and genotype data can be collected using a software tool for collecting and analyzing phenotypic information of patients with genetic disorders ( PhenoTips®) software to facilitate data exchange within the UKT, with external collaborators and data transfer to the Solve-RD project.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
5500
Inclusion Criteria
  • Unclear diagnosis
  • Suspected genetic cause of the disease
Exclusion Criteria
  • Missing informed consent of the patient/ legal guardian

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Molecular geneticDay 1

Verification of the genetic causes of unclear genetic diseases

Secondary Outcome Measures
NameTimeMethod
Characterization of gene defectsDay 1

Further characterization of the identified gene defects

Number of diagnosesDay 1

Improve number of diagnoses of unclear syndromes

Number of patients receiving appropriate therapy after successful diagnosisDay 1

Number of patients receiving appropriate therapy after successful diagnosis

Trial Locations

Locations (1)

University Hospital

🇩🇪

Tübingen, Germany

University Hospital
🇩🇪Tübingen, Germany
Ludger Schoels, Prof. Dr.
Contact
+49 (0)7071
ludger.schoels@uni-tuebingen.de
Olaf Rieß, Prof. Dr.
Contact
+49 (0)7071
olaf.riess@med.uni-tuebingen.de

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.